| 1 |
Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement
Randall A. Oyer et al. · Journal of Clinical Oncology
|
19 May 2022 |
251 |
| 2 |
Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer
Jeffrey J. Tosoian et al. · JAMA Oncology
Open access |
18 Apr 2024 |
64 |
| 3 |
Hepatic kinome atlas: An in‐depth identification of kinase pathways in liver fibrosis of humans and rodents
Justin F. Creeden, Zachary A. Kipp, Mei Ling Xu et al. · Hepatology
Open access |
21 Mar 2022 |
54 |
| 4 |
Next-generation sequencing implicates oncogenic roles for p53 and JAK/STAT signaling in microcystic adnexal carcinomas
May P. Chan, Komal R. Plouffe, Chia‐Jen Liu et al. · Modern Pathology
Open access |
19 Dec 2019 |
45 |
| 5 |
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
Aaron Scott Mansfield et al. · npj Precision Oncology
Open access |
Mar 2022 |
44 |
| 6 |
Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions
Binsheng Gong et al. · Genome biology
Open access151 authors |
16 Apr 2021 |
39 |
| 7 |
A genomic survey of sarcomas on sun-exposed skin reveals distinctive candidate drivers and potentially targetable mutations
Timothy I. Miller, Nicholas A. Zoumberos, Bryan Johnson et al. · Human Pathology
|
12 Jun 2020 |
35 |
| 8 |
Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples
Scott Arthur Tomlins et al. · JCO Precision Oncology
Open access |
19 Aug 2021 |
34 |
| 9 |
Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit
Scott Arthur Tomlins et al. · Communications Medicine
Open access |
7 Feb 2023 |
32 |
| 10 |
Development and Validation of StrataNGS, a Multiplex PCR, Semiconductor Sequencing-Based Comprehensive Genomic Profiling Test
Scott Arthur Tomlins, Daniel H. Hovelson, Paul W. Harms et al. · Journal of Molecular Diagnostics
Open access |
25 Aug 2021 |
25 |
| 11 |
Deep oncopanel sequencing reveals within block position-dependent quality degradation in FFPE processed samples
Yifan Zhang et al. · Genome biology
Open access |
29 Jun 2022 |
17 |
| 12 |
Risk Classification for Interstitial Cystitis/Bladder Pain Syndrome Using Machine Learning Based Predictions
Laura E. Lamb, Joseph Janicki, Sarah N. Bartolone et al. · Urology
Open access |
25 Apr 2024 |
13 |
| 13 |
Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
Benjamin J. Bulen et al. · Cancer Research Communications
Open access |
3 Jul 2023 |
11 |
| 14 |
Non-fusion mutations in endometrial stromal sarcomas: what is the potential impact on tumourigenesis through cell cycle dysregulation?
Snehal Patel, Colin C. McCormack, Jennelle C. Hodge · Journal of Clinical Pathology
|
8 May 2020 |
6 |
| 15 |
Genomic and Immune Landscape of Non–Small Cell Lung Cancer Brain Metastases
Manlu Liu, Justin C. Jagodinsky, S. Carson Callahan et al. · JCO Precision Oncology
|
2025 |
5 |
| 16 |
Rapid Decentralized Prostate Cancer Risk Stratification by Portable Liquid Biopsy Analysis within a Clinical Biosensor Validation Framework
Kevin M. Koo, Grant Phillips, Sriganesh Srihari et al. · Advanced Science
Open access |
27 Jan 2026 |
4 |
| 17 |
Deep oncopanel sequencing reveals fixation time- and within block position-dependent quality degradation in FFPE processed samples
SEQC2 Oncopanel Sequencing Working Group et al. · bioRxiv (Cold Spring Harbor Laboratory)
PreprintOpen access |
7 Apr 2021 |
4 |
| 18 |
Immune and Genomic Heterogeneity of MET-Altered Non–Small Cell Lung Cancer
Manlu Liu, Rachel L. Minne, Saahil Javeri et al. · JCO Precision Oncology
|
Sep 2025 |
2 |
| 19 |
A pathologist’s primer on implementing new standard-of-care molecular biomarker testing for precision prostate cancer management
Steven Christopher Smith, John W. Melson, John Martin Quillin et al. · American Journal of Clinical Pathology
|
22 Jan 2025 |
2 |
| 20 |
A prospective study of minimal residual disease in urological cancers using circulating tumour DNA
Arnav Srivastava, Derrian Cooley, Steven M. Monda et al. · British Journal of Urology
|
13 Aug 2025 |
1 |
| 21 |
A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial
Linda K. Zane et al. · Clinical Cancer Research
Open access |
4 Jun 2025 |
1 |
| 22 |
Hepatic adenomas in males: Is molecular characterization helpful in guiding its management?
Ekta Jain, Sarah Anderson, Eric Ollila et al. · Human Pathology
|
May 2025 |
1 |
| 23 |
Comprehensive genomic profiling of 30,000 consecutive solid tumors
Scott Arthur Tomlins et al. · medRxiv
PreprintOpen access |
22 Nov 2020 |
1 |
| 24 |
Development and Application of MiMouse, a Comprehensive Genomic Profiling Panel for Credentialing Mouse Tumor Models
Kevin Hu, Chia-Jen Liu, Zhaoping Qin et al. · Cancer Research Communications
Open access |
Oct 2025 |
0 |
| 25 |
PP01.106 Validation of Immunotherapy Response Score (IRS) for Predicting Pembrolizumab Monotherapy Benefit in First Line (1L) Non-small cell lung cancer (NSCLC)
Brandi Oakley, Justin S. Moon, M. Kari Connolly et al. · Journal of Thoracic Oncology
Open access |
Jul 2024 |
0 |
| 26 |
P1.21-11 Immunotherapy Response Score (IRS) Predicts Pembrolizumab Clinical Benefit in Patients with NSCLC in TPS≥50%
Jennifer Marie Suga, Sachdev P. Thomas, Ninah S. Achacoso et al. · Journal of Thoracic Oncology
Open access |
31 Oct 2023 |
0 |
| 27 |
Using Real-World Data to Accelerate the Development of Innovative New Cancer Biomarkers
Dan Rhodes · Inside Precision Medicine
|
Feb 2023 |
0 |
| 28 |
Bringing Antibody-Drug Conjugates into the Precision Era
Scott Arthur Tomlins · Inside Precision Medicine
|
Aug 2022 |
0 |
| 29 |
Unlocking the Full Potential of MRD Testing in Patients with Cancer
Scott Arthur Tomlins · Inside Precision Medicine
|
Apr 2022 |
0 |
| 30 |
Prediction of pan-solid tumor pembrolizumab benefit by integrating tumor mutation and gene expression profiling
Nickolay A. Khazanov et al. · Research Square
PreprintOpen access |
5 Jan 2022 |
0 |